Results 221 to 230 of about 718,683 (284)

HRR gene promoter methylation-guided nomogram predicts PARP inhibitor efficacy and progression-free survival in high-grade serous ovarian cancer. [PDF]

Clin Epigenetics
Zhou Z, Ge B, Chen T, Shen S, Tu N, Shen Y.   +5 more
europepmc   +1 more source

Of mice and men—The emerging oral–gut–brain axis of health and disease

Periodontology 2000, EarlyView.
Abstract Objectives Oral health's inextricable links to systemic health are highlighted by the emerging oral–gut–brain axis and other well‐known axes. There is growing evidence of a complex oral–gut–brain axis linking mouth and gut microbiomes with the central nervous system.
Yvonne L. Hernandez‐Kapila, Daniel J. Weisenberger   +1 more
wiley   +1 more source

Quality of Life Measurement in PARP Inhibitor Trials of Epithelial Ovarian Cancer - What Do We Know? [PDF]

Cancer Control
Kumari S, Umadevi K, Sundeep D.
europepmc   +1 more source

Hyperthermia‐induced cytotoxicity and modulation of PD‐L1 and MHC‐I expression in human non‐small cell lung cancer cell lines

Experimental Physiology, EarlyView.
Abstract Hyperthermia has recently been applied to treat human non‐small cell lung cancer (NSCLC). However, the mechanisms underlying cytotoxic sensitivity of NSCLC cells to hyperthermia are not fully understood. In this study, five NSCLC cell lines with different epidermal growth factor receptor (EGFR), Kirsten rat sarcoma and tumor protein p53 ...
Yun‐Chieh Tu, Wei‐Chen Yeh, Yi‐Wei Fang, Ko‐Hsuan Lo, Lei‐Ni Liang, Xu‐Chen Liu, Chia‐Chi Tsai, Chih‐Cheng Cheng, Meng‐Chieh Lin, Hsin‐Hsien Yu, Bor‐Chyuan Su   +10 more
wiley   +1 more source

Intersecting Anemias: PARP Inhibitor-Induced Toxicity and Autoimmune Hemolysis-A Case Report. [PDF]

EJHaem
Dereme J, Asonitis K, Grandoni F, Liapi A, Sarivalasis A, Tsilimidos G.   +5 more
europepmc   +1 more source

Olaparib‐associated cutaneous vasculitis in a patient with breast cancer

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Marcial Álvarez‐Salafranca, Teresa Puértolas, Adrián Diago, María Carmen Gómez‐Mateo   +3 more
wiley   +1 more source

VEGF inhibitor‐induced vascular dysfunction involves redox‐sensitive PARP activation and SIRT1 disruption

Experimental Physiology, EarlyView.
Abstract Vascular endothelial growth factor receptor (VEGFR) inhibitors are effective antiangiogenic agents used in cancer therapy. However, they are associated with cardiovascular disease, including hypertension and vascular dysfunction. The molecular mechanisms underlying these cardiovascular toxicities are unclear, but oxidative stress might be ...
Karla B. Neves, Rheure Alves‐Lopes, Augusto C. Montezano, Rhian M. Touyz   +3 more
wiley   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107. [PDF]

Mol Oncol
Schmitz J, Bartkowiak AL, Rose M, Kolks N, Petzsch P, Solanki V, Stoffel A, Faßbender B, Lepping L, Volkamer J, Köhrer K, Seifert M, Mahmoudi T, Zuiverloon TCM, Niegisch G, Hoffmann MJ.   +15 more
europepmc   +1 more source

Surgical Timing and Survival in Advanced High-Grade Serous Ovarian Cancer in the PARP Inhibitor Era. [PDF]

Cancers (Basel)
Kanno M, Fusegi A, Miyazaki N, Ozawa R, Netsu S, Aoki Y, Omi M, Nomura H, Yunokawa M, Kanao H.   +9 more
europepmc   +1 more source

Characterization of exceptional responders with long-term PARP inhibitor therapy in recurrent ovarian cancer: an analysis of 23 patients from Charité. [PDF]

Arch Gynecol Obstet
Glajzer J, Sehouli J, Woopen H, Braicu EI, Baum J, Grabowski JP.   +5 more
europepmc   +1 more source